ELN and achalasia-alacrima syndrome: Wang et al. recently demonstrated that treatment with HIF-1a inhibitor suppresses the growth of experimental AAAs by the attenuation of mural angiogenesis, as well as the accumulation of inflammatory cells, medial elastin degradation and smooth muscle cell depletion [33].